Agios Pharmaceuticals (AGIO) Projected to Post Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Agios Pharmaceuticals to post earnings of ($1.80) per share and revenue of $9.86 million for the quarter.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, analysts expect Agios Pharmaceuticals to post $-7 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $29.62 on Tuesday. The business has a 50 day moving average of $30.21 and a 200-day moving average of $38.12. Agios Pharmaceuticals has a 1 year low of $23.42 and a 1 year high of $62.58. The company has a market capitalization of $1.70 billion, a P/E ratio of 2.61 and a beta of 0.83.

Insider Transactions at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This represents a 4.78 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.93% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 target price for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $56.57.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.